Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection

• Published in: Antimicrobial agents and chemotherapy Vol. 63; no. 2
• Main Authors: Yee, Ka Lai, Kleijn, Huub Jan, Kerbusch, Thomas, Matthews, Randolph P., Dorr, Mary Beth, Garey, Kevin W., Wrishko, Rebecca E.
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.02.2019
• Subjects: Antibodies, Monoclonal; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Broadly Neutralizing Antibodies; Broadly Neutralizing Antibodies - therapeutic use; Clinical Therapeutics; Clostridium difficile - drug effects; Clostridium difficile - pathogenicity; Clostridium Infections; Clostridium Infections - drug therapy; Clostridium Infections - metabolism; Humans; Clostridium difficile; bezlotoxumab; population pharmacokinetics
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/AAC.01971-18

The fully human monoclonal antibody bezlotoxumab is indicated for preventing the recurrence of Clostridioides difficile (formerly Clostridium difficile ) infection (CDI) in adults who receive antibacterial treatment for CDI and who are at high risk for a CDI recurrence. The efficacy and safety of 10-mg/kg of body weight bezlotoxumab were demonstrated in two phase 3 trials: the MODIFY I (ClinicalTrials.gov registration number NCT01241552) and MODIFY II (ClinicalTrials.gov registration number NCT01513239) trials. The fully human monoclonal antibody bezlotoxumab is indicated for preventing the recurrence of Clostridioides difficile (formerly Clostridium difficile ) infection (CDI) in adults who receive antibacterial treatment for CDI and who are at high risk for a CDI recurrence. The efficacy and safety of 10-mg/kg of body weight bezlotoxumab were demonstrated in two phase 3 trials: the MODIFY I (ClinicalTrials.gov registration number NCT01241552) and MODIFY II (ClinicalTrials.gov registration number NCT01513239) trials. Here, a population pharmacokinetic (popPK) analysis, performed using data from the MODIFY I and II trials ( n = 1,515) and from three phase 1 trials ( n = 72) to characterize bezlotoxumab pharmacokinetics (PK) in phase 3 clinical trial participants and in healthy subjects, is reported. A stepwise covariate search was conducted to identify factors influencing PK. Post hoc -estimated bezlotoxumab exposures from the popPK model were used to conduct an exposure-response analysis for CDI recurrence. Bezlotoxumab PK were described by a two-compartment model with linear elimination and allometric scaling for clearance and the volume of distribution by body weight. Although the final popPK model included gender, ethnicity (Japanese descent), race (black versus nonblack), and albumin level as significant covariates, the impact of these factors was not clinically meaningful, based on the totality of the PK and clinical experience. Exposure-response analysis of CDI recurrence demonstrated a similar low rate of CDI recurrence over the entire range of exposures achieved in the phase 3 trials, indicating that exposures were on the maximal response plateau of the exposure-response curve. Overall, the analyses confirmed the appropriateness of the 10-mg/kg dose across the phase 3 trial population with no dose adjustments necessary over a broad demographic background.